Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%
Market cap
$24.9B
P/E
58.1×
Fwd P/E
57.3×
Dividend yield
—
F-score
9/9
ROIC
21.6%
Net debt / EBITDA
−2.2×
Dividend safety
n/a

Incyte Corporation (INCY) Total debt

Alert me on Total debt

Incyte Corporation's total debt at the end of fiscal 2025 was $30.2M, down 9.97% from $33.5M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $27.6M. Over the past ten years it has ranged from $17.4M (fiscal 2018) to $651.5M (fiscal 2016); the current reading is higher than 45% of that period. Incyte Corporation ranks 172nd of 569 Biotechnology companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2025 $30.2M (9.97%)
FY2024 $33.5M 15.02%
FY2023 $29.2M (3.06%)
FY2022 $30.1M (4.90%)
FY2021 $31.6M (2.89%)
FY2020 $32.6M (35.14%)
FY2019 $50.2M 188.05%
FY2018 $17.4M (27.36%)
FY2017 $24.0M (96.32%)
FY2016 $651.5M 5.10%

Quarterly newest first

Period Total debt Change
Sep 2026 $27.6M (2.77%)
Jun 2026 $28.4M (3.38%)
Mar 2026 $29.4M (2.60%)
Dec 2025 $30.2M (2.21%)
43 more quarters

Against its own ten years

Low $17.4M High $651.5M
Ten-year median $31.6M
Current reading's percentile 45

Total debt against peers

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on INCY